Related Experiment Video

Updated: May 14, 2026

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats
05:55

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

Genetic risk factors for glucocorticoid-induced osteonecrosis: a meta-analysis

Li-Li Gong1, Lian-Hua Fang, He-Yao Wang

  • 1Beijing Chao-Yang Hospital, Affiliate of Capital Medical University, Beijing 100020, China. hongllh@126.com

Steroids
|January 30, 2013
PubMed

Insights

Glucocorticoid-induced osteonecrosis risk is linked to specific gene variations. The PAI-1 4G/5G and ABCB1 C3435T polymorphisms are identified as potential risk factors for developing this condition.

Area of Science:

  • Genetics
  • Pharmacogenomics
  • Bone Biology

Background:

  • Glucocorticoid-induced osteonecrosis is a severe adverse event.
  • Genetic predispositions may influence the risk of developing osteonecrosis.
  • Identifying genetic risk factors can aid in prevention and personalized treatment strategies.

Purpose of the Study:

  • To investigate the association between polymorphisms in target genes and the risk of corticosteroid-induced osteonecrosis.
  • To conduct a meta-analysis of published literature to confirm these genetic associations.
  • To identify specific single nucleotide polymorphisms (SNPs) that confer increased risk.

Main Methods:

  • A comprehensive literature search was performed in PubMed and EMBASE.
  • Meta-analyses were conducted on eligible publications using fixed- or random-effects models.
  • Pooled odds ratios (OR) and 95% confidence intervals (CI) were calculated for selected SNPs in PAI-1, MTHFR, and ABCB1 genes.

Main Results:

  • The PAI-1 4G allele was associated with an increased risk of osteonecrosis (OR=1.932).
  • The ABCB1 C3435T polymorphism showed an increased risk of osteonecrosis with the C allele (OR=1.668).
  • No significant association was found for MTHFR C677T and ABCB1 G2677T/A polymorphisms.

Conclusions:

  • PAI-1 4G/5G and ABCB1 C3435T polymorphisms are potential risk factors for glucocorticoid-induced osteonecrosis.
  • These findings contribute to understanding the genetic basis of corticosteroid-induced osteonecrosis.
  • Further research may validate these genetic markers for clinical risk assessment.

Related Concept Videos

Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...